Imara Inc.(IMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRA Imara Inc.

Trading 11-22 14:04:38 EST

25.28

+0.00

0.00%

High25.28	Low25.28	Vol0.00
Open25.28	D1 Closing25.28	Amplitude0.00%
Mkt Cap165.80M	Tradable Cap49.81M	Total Shares6.56M
T/O1.60M	T/O Rate0.00%	Tradable Shares1.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMRA","market":"US","secType":"STK","nameCN":"Imara Inc.","latestPrice":25.28,"timestamp":1677186000000,"preClose":25.28,"halted":8,"volume":0,"delay":0,"floatShares":1970226,"shares":6558475,"eps":0.22642,"marketStatus":"Trading","change":0,"latestTime":"11-22 14:04:38 EST","open":25.28,"high":25.28,"low":25.28,"amount":1597939.1066573998,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.22642,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"symbolChange":{"newSymbol":"ELVN","executeDate":"2023-02-24"},"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":25.28,"volumeRatio":0},"requestUrl":"/m/hq/s/IMRA","defaultTab":"news","newsList":[{"id":"2313819853","title":"Press Release: Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2313819853","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2313819853?lang=en_us&edition=fundamental","pubTime":"2023-02-24 06:20","pubTimestamp":1677190800,"startTime":"0","endTime":"0","summary":"Combined company will be focused on advancing Enliven's clinical-stage pipeline of precision oncology programs. Shares to trade on Nasdaq under the new ticker symbol \"ELVN\" on February 24, 2023. Combined company is expected to have cash runway into early 2026. BOULDER, Colo., Feb. 23, 2023  -- Enliven Therapeutics, Inc.  , a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the completion of its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN","IMRA"],"gpt_icon":0},{"id":"2313076110","title":"Imara Announces Stockholder Approval of Merger With Enliven","url":"https://stock-news.laohu8.com/highlight/detail?id=2313076110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2313076110?lang=en_us&edition=fundamental","pubTime":"2023-02-22 21:01","pubTimestamp":1677070860,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2023/02/22/2613692/0/en/Imara-Announces-Stockholder-Approval-of-Merger-With-Enliven.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMRA","ELVN"],"gpt_icon":0},{"id":"2310529414","title":"BML Investment Partners Increases Position in Imara (IMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2310529414","media":"Nasdaq","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2310529414?lang=en_us&edition=fundamental","pubTime":"2023-02-09 06:02","pubTimestamp":1675893739,"startTime":"0","endTime":"0","summary":"BML Investment Partners Increases Position in Imara (IMRA)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiWGh0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvYm1sLWludmVzdG1lbnQtcGFydG5lcnMtaW5jcmVhc2VzLXBvc2l0aW9uLWluLWltYXJhLWltcmHSAQA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiWGh0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvYm1sLWludmVzdG1lbnQtcGFydG5lcnMtaW5jcmVhc2VzLXBvc2l0aW9uLWluLWltYXJhLWltcmHSAQA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2283233440","title":"Short Interest in IMARA Inc. (NASDAQ:IMRA) Grows By 56.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2283233440","media":"MarketBeat","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2283233440?lang=en_us&edition=fundamental","pubTime":"2022-11-15 05:47","pubTimestamp":1668462432,"startTime":"0","endTime":"0","summary":"Short Interest in IMARA Inc. (NASDAQ:IMRA) Grows By 56.9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/__i/rss/rd/articles/CBMiVGh0dHBzOi8vd3d3Lm1hcmtldGJlYXQuY29tL2luc3RhbnQtYWxlcnRzL25hc2RhcS1pbXJhLW9wdGlvbnMtZGF0YS1yZXBvcnQtMjAyMi0xMS0yL9IBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/__i/rss/rd/articles/CBMiVGh0dHBzOi8vd3d3Lm1hcmtldGJlYXQuY29tL2luc3RhbnQtYWxlcnRzL25hc2RhcS1pbXJhLW9wdGlvbnMtZGF0YS1yZXBvcnQtMjAyMi0xMS0yL9IBAA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["TERN","BK4539","CRCT","NASDAQ","BOLT","BK4007","IMRA","BK4191","BK4139"],"gpt_icon":0},{"id":"2276814542","title":"Imara Shares Fall 11% After Friday Gains On Merger Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2276814542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2276814542?lang=en_us&edition=fundamental","pubTime":"2022-10-18 00:11","pubTimestamp":1666023060,"startTime":"0","endTime":"0","summary":"Shares of Imara Inc. fell 11% to $3.39 Monday after the company's all-stock deal to merge with oncology company Enliven Therapeutics Inc. sent shares higher Friday.The combined company, which will be called Enliven Therapeutics Inc., will focus on Enliven's pipeline of precision oncology product candidates, the companies said late Thursday. The combined company will trade on the Nasdaq Global Select Market under the ticker symbol ELVN.Shareholders of both companies still need to approve the merg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRA","BK4007"],"gpt_icon":0},{"id":"2276016728","title":"NGM, PEGY and IMRA among pre market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2276016728","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2276016728?lang=en_us&edition=fundamental","pubTime":"2022-10-17 20:48","pubTimestamp":1666010888,"startTime":"0","endTime":"0","summary":"NGM Biopharmaceuticals  -67%announces topline results from the CATALINA Phase 2 trial of NGM621 in patients with Geographic Atrophy secondary to age-related macular degeneration.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3891797-ngm-pegy-and-imra-among-pre-market-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4563","IMRA","PEGY","BK4007","NGM","BK4096"],"gpt_icon":0},{"id":"2275895164","title":"Avenue, IMARA lead healthcare gainers; Galecto, Travere among losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2275895164","media":"Seeking Alpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275895164?lang=en_us&edition=fundamental","pubTime":"2022-10-15 02:34","pubTimestamp":1665772498,"startTime":"0","endTime":"0","summary":"Avenue, IMARA lead healthcare gainers; Galecto, Travere among losers","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://seekingalpha.com/news/3891438-avenue-imara-lead-healthcare-gainers-galecto-travere-among-losers","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3891438-avenue-imara-lead-healthcare-gainers-galecto-travere-among-losers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["GLTO","BK4007","IMRA","BK4139"],"gpt_icon":0},{"id":"2275558529","title":"Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply","url":"https://stock-news.laohu8.com/highlight/detail?id=2275558529","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275558529?lang=en_us&edition=fundamental","pubTime":"2022-10-15 00:05","pubTimestamp":1665763558,"startTime":"0","endTime":"0","summary":"U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/22/10/29271386/nasdaq-tumbles-over-200-points-crude-oil-falls-sharply","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RBT","BK4122","FRC","BK4139","BK4211","BK4548","BK4023","RETA","BK4504","BK4534","IMRA","LU1989772840.SGD","LU1074936037.SGD","PCOM","BK4007","LU1668664300.SGD","BK4581","BK4196","NTNX","BK4127","LU0971096721.USD","ZYME","LU1989772923.USD","MS","LU0106831901.USD","LU1363072403.SGD","NVOS"],"gpt_icon":0},{"id":"2275792954","title":"Imara Agrees To Merge With Precision Oncology Player, Shares Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2275792954","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275792954?lang=en_us&edition=fundamental","pubTime":"2022-10-14 21:15","pubTimestamp":1665753356,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics IncandImara Inc agreed to mergein an all-stock transaction.The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates.Enliven is advancing two parallel lead product candidates:. ELVN-002 for HER2 mutant lung cancer and other HER2-driven tumor types.In September, Imaradivested tovinontrine and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.The combined company is expected to operate under Enliven The","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VmLMq6OYU.ZA1_pGZlN4aw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/SK.Nre0mgvGVoMBGezGXTQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/e19f9d8cab4de816f4a126622ab6dd71","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VmLMq6OYU.ZA1_pGZlN4aw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/SK.Nre0mgvGVoMBGezGXTQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/e19f9d8cab4de816f4a126622ab6dd71"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imara-agrees-merge-precision-oncology-131556148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2275863739","title":"BRIEF-Arix Bioscience Says Portfolio Co Imara Announces Merger Deal With Enliven Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2275863739","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275863739?lang=en_us&edition=fundamental","pubTime":"2022-10-14 14:18","pubTimestamp":1665728296,"startTime":"0","endTime":"0","summary":"Oct 14  - Arix Bioscience PLC   :   * REG-ARIX BIOSCIENCE PLC PORTFOLIO COMPANY IMARA ANNOUNCES MERGER AGREEMENT WITH ENLIVEN THERAPEUTICS   * ARIX BIOSCIENCE PLC - PORTFOLIO COMPANY IMARA ANNOUNCES MERGER AGREEMENT WITH ENLIVEN THERAPEUTICS   * ARIX BIOSCIENCE PLC - TRANSACTION TO CONCURRENTLY RAISE ABOUT $165 MILLION IN A PRIVATE FINANCINGSource text for Eikon:    Further company coverage:   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2275677102","title":"After-Hours Movers: Imara Gains on Merger, Travere Therapeutics Falls on PDUFA Delay","url":"https://stock-news.laohu8.com/highlight/detail?id=2275677102","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275677102?lang=en_us&edition=fundamental","pubTime":"2022-10-14 07:17","pubTimestamp":1665703040,"startTime":"0","endTime":"0","summary":"After-Hours Stock Movers:$Imara Inc.$  22.5% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc.  announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.$Eargo, Inc.$  8.4% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time .$Trave","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=20701851","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["EAR","TVTX","IMRA"],"gpt_icon":0},{"id":"2275771706","title":"Imara Shares Climb 29% After Hours on Merger Plans with Enliven Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2275771706","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275771706?lang=en_us&edition=fundamental","pubTime":"2022-10-14 05:45","pubTimestamp":1665697500,"startTime":"0","endTime":"0","summary":"Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal.The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday.The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticke","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2275672204","title":"Imara, Enliven Therapeutics Agree to Merge in All-Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2275672204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275672204?lang=en_us&edition=fundamental","pubTime":"2022-10-14 05:06","pubTimestamp":1665695160,"startTime":"0","endTime":"0","summary":"Imara Inc. and Enliven Therapeutics Inc. have agreed to merge in an all-stock deal.The companies said Thursday the combined company, which will be called Enliven Therapeutics Inc., will focus on Enliven's pipeline of precision oncology product candidates. The company will trade on the Nasdaq Global Select Market under the ticker symbol ELVN, they said.Shareholders of both companies still need to approve the merger, though Imara and Enliven said they expect the deal to close in the first quarter ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRA","BK4007","BK4080","ADC"],"gpt_icon":0},{"id":"2275460822","title":"Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2275460822","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275460822?lang=en_us&edition=fundamental","pubTime":"2022-10-14 04:49","pubTimestamp":1665694183,"startTime":"0","endTime":"0","summary":"Pharmaceutical firms Enliven Therapeutics and Imara  have agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates, IMRA said in a statement on Thursday. Enliven has two cancer drug candidates.  The merged entity will be renamed Enliven Therapeutics and is expected to trade on the Nasdaq Global Select Market under the ticker symbol ELVN. To support the merger, Enliven also intends to raise about $165M in","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1319579558/image_1319579558.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1319579558/image_1319579558.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/3891238-cancer-drug-developer-enliven-therapeutics-and-imara-to-merge-in-all-stock-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2275674364","title":"Press Release: Enliven Therapeutics and Imara Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2275674364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2275674364?lang=en_us&edition=fundamental","pubTime":"2022-10-14 04:35","pubTimestamp":1665693300,"startTime":"0","endTime":"0","summary":"-- Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company. focused on advancing Enliven's portfolio of precision oncology programs. -- Combined company is expected to have a cash balance of approximately $300. million at close, which is expected to provide cash runway through. -- Planned concurrent financing of approximately $165 million co-led by new. investors Fairmount and Venrock Healthcare Capital Partners, with. participation from additional new investors including Fideli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IMRA"],"gpt_icon":0},{"id":"2272008574","title":"Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2272008574","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2272008574?lang=en_us&edition=fundamental","pubTime":"2022-10-03 21:40","pubTimestamp":1664804401,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Catalyst Pharmaceutical  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Catalyst Pharmaceutical is one of 1193 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank cons","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oRiKpZCPa_GSPVlAqOvGAQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oRiKpZCPa_GSPVlAqOvGAQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/catalyst-pharmaceuticals-cprx-stock-outpacing-134001530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CPRX","IMRA"],"gpt_icon":0},{"id":"2271723481","title":"Imara: Potential Liquidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2271723481","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2271723481?lang=en_us&edition=fundamental","pubTime":"2022-09-30 03:06","pubTimestamp":1664478406,"startTime":"0","endTime":"0","summary":"stockarm/iStock via Getty ImagesImara (NASDAQ:IMRA) is a failed $60m MCAP biotech company trading at a 37% discount to its Pro Forma net cash levels. In April, the company reduced its workforce by aro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4543883-imara-potential-liquidation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IMRA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imaratx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.220721},{"month":2,"riseRate":0.666667,"avgChangeRate":0.142821},{"month":3,"riseRate":0.5,"avgChangeRate":-0.046393},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.106251},{"month":5,"riseRate":0.333333,"avgChangeRate":0.266377},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.026685},{"month":7,"riseRate":0,"avgChangeRate":-0.209326},{"month":8,"riseRate":0.666667,"avgChangeRate":0.016098},{"month":9,"riseRate":0.333333,"avgChangeRate":0.219731},{"month":10,"riseRate":0.333333,"avgChangeRate":0.202336},{"month":11,"riseRate":0.333333,"avgChangeRate":0.170628},{"month":12,"riseRate":0,"avgChangeRate":-0.169953}],"exchange":"NASDAQ","name":"Imara Inc.","nameEN":"Imara Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imara Inc.(IMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imara Inc.(IMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imara Inc.,IMRA,Imara Inc.股票,Imara Inc.股票老虎,Imara Inc.股票老虎国际,Imara Inc.行情,Imara Inc.股票行情,Imara Inc.股价,Imara Inc.股市,Imara Inc.股票价格,Imara Inc.股票交易,Imara Inc.股票购买,Imara Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imara Inc.(IMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imara Inc.(IMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction